Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX).

Sundby Hall K, Bruland ØS, Bjerkehagen B, Zaikova O, Engellau J, Hagberg O, Hansson L, Hagberg H, Ahlström M, Knobel H, Papworth K, Zemmler M, Goplen D, Bauer HCF, Eriksson M.

Eur J Cancer. 2018 Aug;99:78-85. doi: 10.1016/j.ejca.2018.05.011. Epub 2018 Jun 19.

PMID:
29929092
2.

Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223.

Herlofson BB, Kjølle GK, Westgaard KL, Løndalen AM, Bruland ØS.

Clin Genitourin Cancer. 2018 May 16. pii: S1558-7673(18)30364-1. doi: 10.1016/j.clgc.2018.05.003. [Epub ahead of print] No abstract available.

PMID:
29861164
3.

Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study.

Hølmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland ØS, Hall KS, Boye K.

Ann Surg Oncol. 2018 May;25(5):1133-1139. doi: 10.1245/s10434-018-6353-5. Epub 2018 Feb 12.

PMID:
29435684
4.

Therapeutic Effect of α-Emitting 224Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer.

Westrøm S, Bønsdorff TB, Bruland ØS, Larsen RH.

Transl Oncol. 2018 Apr;11(2):259-267. doi: 10.1016/j.tranon.2017.12.011. Epub 2018 Jan 28.

5.

Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice.

Westrøm S, Malenge M, Jorstad IS, Napoli E, Bruland ØS, Bønsdorff TB, Larsen RH.

J Labelled Comp Radiopharm. 2018 May 30;61(6):472-486. doi: 10.1002/jlcr.3610. Epub 2018 Mar 12.

6.

Genotype and risk of tumour rupture in gastrointestinal stromal tumour.

Boye K, Berner JM, Hompland I, Bruland ØS, Stoldt S, Sundby Hall K, Bjerkehagen B, Hølmebakk T.

Br J Surg. 2018 Jan;105(2):e169-e175. doi: 10.1002/bjs.10743.

PMID:
29341147
7.

Palliative Treatment of Cancer-Related Pain [Internet].

Kongsgaard U, Kaasa S, Dale O, Ottesen S, Nordøy T, Hessling SE, von Hofacker S, Bruland ØS, Lyngstadaas A.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005 Dec.

8.

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S.

Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30516-X. doi: 10.1016/j.eururo.2017.06.021. [Epub ahead of print]

9.

Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort.

Hompland I, Bruland ØS, Hølmebakk T, Poulsen JP, Stoldt S, Hall KS, Boye K.

Acta Oncol. 2017 Oct;56(10):1317-1323. doi: 10.1080/0284186X.2017.1330555. Epub 2017 May 30.

PMID:
28557540
10.

Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour.

Hompland I, Bruland ØS, Ubhayasekhera K, Bergquist J, Boye K.

Clin Sarcoma Res. 2016 Dec 15;6:21. doi: 10.1186/s13569-016-0062-2. eCollection 2016.

11.

Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years.

König M, Osnes TA, Lobmaier I, Bjerkehagen B, Bruland ØS, Sundby Hall K, Meling TR.

Neurosurg Rev. 2017 Jul;40(3):449-460. doi: 10.1007/s10143-016-0802-z. Epub 2016 Nov 17.

PMID:
27858303
12.

Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma.

Westrøm S, Bønsdorff TB, Abbas N, Bruland ØS, Jonasdottir TJ, Mælandsmo GM, Larsen RH.

PLoS One. 2016 Oct 24;11(10):e0165382. doi: 10.1371/journal.pone.0165382. eCollection 2016.

13.

Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene.

Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA.

PLoS One. 2016 Sep 29;11(9):e0163859. doi: 10.1371/journal.pone.0163859. eCollection 2016.

14.

Negative and Positive Consequences of Cancer Treatment Experienced by Long-term Osteosarcoma Survivors: A Qualitative Study.

Fauske L, Bondevik H, Bruland ØS, Ozakinci G.

Anticancer Res. 2015 Nov;35(11):6081-90.

PMID:
26504033
15.

Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?

Hompland I, Bruland ØS.

Anticancer Res. 2015 Nov;35(11):5759-65. Review.

PMID:
26503996
16.

Clinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009.

Berner K, Johannesen TB, Bruland ØS.

Sarcoma. 2015;2015:917679. doi: 10.1155/2015/917679. Epub 2015 Aug 30.

17.

Cured of primary bone cancer, but at what cost: a qualitative study of functional impairment and lost opportunities.

Fauske L, Bruland OS, Grov EK, Bondevik H.

Sarcoma. 2015;2015:484196. doi: 10.1155/2015/484196. Epub 2015 Apr 9.

18.

Extraskeletal osteosarcoma in Norway, between 1975 and 2009, and a brief review of the literature.

Berner K, Bjerkehagen B, Bruland ØS, Berner A.

Anticancer Res. 2015 Apr;35(4):2129-40.

PMID:
25862869
19.

Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.

Humm JL, Sartor O, Parker C, Bruland OS, Macklis R.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):898-906. doi: 10.1016/j.ijrobp.2014.12.061. Review.

PMID:
25832684
20.

Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.

Berner K, Hall KS, Monge OR, Weedon-Fekjær H, Zaikova O, Bruland ØS.

Sarcoma. 2015;2015:516843. doi: 10.1155/2015/516843. Epub 2015 Feb 17.

21.

Influence of multiple UV exposures on serum cobalamin and vitamin D levels in healthy females.

Juzeniene A, Baturaite Z, Lagunova Z, Grigalavicius M, Porojnicu AC, Bruland ØS, Moan J.

Scand J Public Health. 2015 May;43(3):324-30. doi: 10.1177/1403494815572206. Epub 2015 Mar 4.

PMID:
25740614
22.

Primary bone cancer in Leonbergers may be associated with a higher bodyweight during adolescence.

Anfinsen KP, Grotmol T, Bruland OS, Trangerud C, Jonasdottir TJ.

Prev Vet Med. 2015 Apr 1;119(1-2):48-53. doi: 10.1016/j.prevetmed.2015.02.003. Epub 2015 Feb 14. Erratum in: Prev Vet Med. 2015 Jun 15;120(2):252. Trangerud, Cathrine [added].

PMID:
25732913
23.

Vitamin D levels and dietary intake among patients with benign soft tissue tumors and sarcomas.

Juzeniene A, Porojnicu AC, Baturaite Z, Lagunova Z, Aksnes L, Bruland ØS, Moan J.

Anticancer Res. 2015 Feb;35(2):1171-80.

PMID:
25667508
24.

177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice.

Repetto-Llamazares AH, Larsen RH, Giusti AM, Riccardi E, Bruland ØS, Selbo PK, Dahle J.

PLoS One. 2014 Jul 28;9(7):e103070. doi: 10.1371/journal.pone.0103070. eCollection 2014.

25.

Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.

Repetto-Llamazares A, Abbas N, Bruland ØS, Dahle J, Larsen RH.

Anticancer Res. 2014 Jul;34(7):3263-9.

PMID:
24982330
26.

Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma.

Berner K, Johannesen TB, Berner A, Haugland HK, Bjerkehagen B, Bøhler PJ, Bruland ØS.

Acta Oncol. 2015 Jan;54(1):25-33. doi: 10.3109/0284186X.2014.923934. Epub 2014 Jun 24.

27.

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C.

Lancet Oncol. 2014 Jun;15(7):738-46. doi: 10.1016/S1470-2045(14)70183-4. Epub 2014 May 13.

PMID:
24836273
28.

Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma - a predictor of outcome?

Ohnstad HO, Bruland OS, Taksdal I, Bjerkehagen B, Nenadovic M, Sæter G, Jørgensen LH, Hall KS.

Acta Oncol. 2014 Sep;53(9):1180-7. doi: 10.3109/0284186X.2014.899433. Epub 2014 Apr 3.

PMID:
24697744
29.

Radiotherapy for spinal metastases from breast cancer with emphasis on local disease control and pain response using repeated MRI.

Switlyk MD, Bruland ØS, Skjeldal S, Hald JK, Seierstad T, Zaikova O.

J Bone Oncol. 2014 Mar 12;3(1):5-9. doi: 10.1016/j.jbo.2014.02.003. eCollection 2014 Mar.

30.

Malignant phyllodes tumor and acute megakaryoblastic leukemia sharing a common clonal origin.

Fløisand Y, Beiske K, Tjønnfjord GE, Heldal D, Bjerkehagen B, Revheim ME, Heim S, Bruland OS, Hall KS, Tierens A, Delabie J.

Case Rep Hematol. 2013;2013:934781. doi: 10.1155/2013/934781. Epub 2013 Dec 17.

31.

Two cases with fatal outcome following total lung irradiation for metastatic bone sarcoma.

Lia K, Bruland ØS, Randem HL, Aksnes LH, Poulsen JP, Taksdal I, Sundby Hall K.

J Bone Oncol. 2013 Oct 11;2(4):174-9. doi: 10.1016/j.jbo.2013.09.002. eCollection 2013 Dec.

32.

The clinical impact of mean vessel size and solidity in breast carcinoma patients.

Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR.

PLoS One. 2013 Oct 11;8(10):e75954. doi: 10.1371/journal.pone.0075954. eCollection 2013.

33.

Alpha emitter radium-223 and survival in metastatic prostate cancer.

Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators.

N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.

34.

Incidence and mortality of second sarcomas - a population-based study.

Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Bruland ØS, Smeland S, Johannesen TB, Fosså SD.

Eur J Cancer. 2013 Oct;49(15):3292-302. doi: 10.1016/j.ejca.2013.05.017. Epub 2013 Jun 17.

PMID:
23787025
35.

Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall.

Jebsen NL, Engellau J, Engström K, Bauer HC, Monge OR, Muren LP, Eide GE, Trovik CS, Bruland OS.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):949-55. doi: 10.1016/j.ijrobp.2013.04.015. Epub 2013 May 29.

36.

Multimodal functional imaging for early response assessment in GIST patients treated with imatinib.

Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L, Seierstad T.

Acta Oncol. 2014 Jan;53(1):143-8. doi: 10.3109/0284186X.2013.798428. Epub 2013 May 28. No abstract available.

37.

Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial.

Lagunova Z, Porojnicu AC, Aksnes L, Holick MF, Iani V, Bruland OS, Moan J.

Br J Dermatol. 2013 Aug;169(2):434-40. doi: 10.1111/bjd.12349.

PMID:
23551243
38.

Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts.

Abbas N, Heyerdahl H, Bruland ØS, Brevik EM, Dahle J.

Curr Radiopharm. 2013 Jun 6;6(2):78-86.

PMID:
23551110
39.

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H.

Revheim ME, Kristian A, Malinen E, Bruland ØS, Berner JM, Holm R, Joensuu H, Seierstad T.

Acta Oncol. 2013 May;52(4):776-82. doi: 10.3109/0284186X.2013.770920. Epub 2013 Mar 13.

40.

Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.

Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH.

Anticancer Res. 2013 Jan;33(1):85-95.

PMID:
23267131
41.

Quantitative dynamic ¹⁸FDG-PET and tracer kinetic analysis of soft tissue sarcomas.

Rusten E, Rødal J, Revheim ME, Skretting A, Bruland OS, Malinen E.

Acta Oncol. 2013 Aug;52(6):1160-7. doi: 10.3109/0284186X.2012.728713. Epub 2012 Dec 3.

PMID:
23198721
42.

Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.

Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, O'Bryan-Tear CG, Thuresson M, Bolstad B, Bruland ØS.

Clin Genitourin Cancer. 2013 Mar;11(1):20-6. doi: 10.1016/j.clgc.2012.07.002. Epub 2012 Sep 26.

PMID:
23021204
43.

Superficial-spreading and nodular melanomas in Norway: a comparison by body site distribution and latitude gradients.

Micu E, Baturaite Z, Juzeniene A, Bruland ØS, Moan JE.

Melanoma Res. 2012 Dec;22(6):460-5. doi: 10.1097/CMR.0b013e3283599cc3.

PMID:
23010822
44.

Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.

Abbas N, Bruland ØS, Brevik EM, Dahle J.

Nucl Med Commun. 2012 Aug;33(8):838-47. doi: 10.1097/MNM.0b013e328354df7c.

PMID:
22643311
45.

Targeted radio-nuclide therapy of skeletal metastases.

Sartor O, Hoskin P, Bruland OS.

Cancer Treat Rev. 2013 Feb;39(1):18-26. doi: 10.1016/j.ctrv.2012.03.006. Epub 2012 Apr 24. Review.

PMID:
22534284
46.

Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern.

Namløs HM, Kresse SH, Müller CR, Henriksen J, Holdhus R, Sæter G, Bruland OS, Bjerkehagen B, Steen VM, Myklebost O.

Sarcoma. 2012;2012:639038. doi: 10.1155/2012/639038. Epub 2012 Feb 28.

47.

A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland ØS.

Eur J Cancer. 2012 Mar;48(5):678-86. doi: 10.1016/j.ejca.2011.12.023. Epub 2012 Feb 15. Review.

48.

Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.

Abbas N, Heyerdahl H, Bruland OS, Borrebæk J, Nesland J, Dahle J.

EJNMMI Res. 2011 Aug 24;1(1):18. doi: 10.1186/2191-219X-1-18.

49.

Breed-specific incidence rates of canine primary bone tumors--a population based survey of dogs in Norway.

Anfinsen KP, Grotmol T, Bruland OS, Jonasdottir TJ.

Can J Vet Res. 2011 Jul;75(3):209-15.

50.

Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates.

Dahle J, Abbas N, Bruland ØS, Larsen RH.

Curr Radiopharm. 2011 Oct;4(4):321-8. Review.

PMID:
22202154

Supplemental Content

Loading ...
Support Center